Woodford Woes Drag On For Immunocore

Unrealistic Valuations Holding Private Firms Back

Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.

Oxford
Oxford, home to T-cell receptor immunotherapy company Immunocore

More from Business

More from Scrip